Treatment study for people with advanced colorectal, gastric and gastro-esophageal junction tumors
Study Contact Information:
Questions about the study can be directed to the study contacts listed below or to Dr. Patricia Delaite at [email protected]
The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers MSI-High or dMMR. Participants will receive the vaccine in combination with the immunotherapy drug Keytruda (pembrolizumab). NOTE: This study is no longer enrolling people.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.